Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing risk factors for cardiovascular diseases, availability of advanced diagnostic methods, and rising prevalence of hypercholesterolemia.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The cardiovascular therapeutics market is segmented as below:
By Distribution Channel
- Hospital pharmacy
- Retail Pharmacy
- Online pharmacy
By Type
- Antithrombotic drugs
- Hypolipidemic drugs
- Others
By Route Of Administration
- Oral
- Injectable
- Transdermal
By Geographical Landscape
- Asia
- North America
- Europe
- Rest of World (ROW)
The report on the cardiovascular therapeutics market covers the following areas:
- Cardiovascular Therapeutics Market sizing
- Cardiovascular Therapeutics Market forecast
- Cardiovascular Therapeutics Market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
Executive Summary
The following companies are recognized as the key players in the global cardiovascular therapeutics market: Abbott Laboratories, Acutus Medical Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Viatris Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is advent of novel oral anticoagulants (NOACs)."
According to the report, one of the major drivers for this market is the increasing risk factors for cardiovascular diseases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Acutus Medical Inc.
- Amgen Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- Aurobindo Pharma Ltd.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Co.
- Daiichi Sankyo Co. Ltd.
- Dr Reddys Laboratories Ltd.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Johnson and Johnson Services Inc.
- Merck and Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Viatris Inc.

